SynaptaGenX is a result of over 30 years of research, including 23 clinical trials, led by Dr. Kenneth Blum, Ph. D, the pioneer of Amino Acid Therapy for addiction recovery.
SynaptaGenX utilizes a patented liposomal technology that maximizes bio-availability.
SynaptaGenX is an all-natural Dopamine Agonist, which has been shown in numerous studies to promote Dopamine, as well as Serotonin, and Endorphins, important neurotransmitters responsible for brain reward.
SynaptaGenX assists individuals with Reward Deficiency System (RDS) as described by Dr. Kenneth Blum, PH. D. Individuals with RDS are unable to produce an adequate feeling of well-being and consequently often self-medicate with substances that help raise the levels of “feel-good” chemicals (i.e. dopamine) in their system–if only temporarily.
SynaptaGenX contains patented KB220Z neuroadaptagen technology, which has been shown to reduce or eliminate excessive desires for unhealthy behaviors and pleasure-inducing substances, including psychostimulant use/abuse, alcohol, and excessive food cravings. The Neuro-nutrients in SynaptaGenX help promote optimal dopamine function; normalize satiety and pleasure satisfaction from normally enjoyable activities and experiences; improve energy regulation, reduce stress, promote well-being, and increase feelings of happiness.
SynaptaGenX is a proprietary KB220Z neuro-nutraceutical adaptogen formula that has been used in extensive clinical trials as well as pre-clinical animal studies. These studies, conducted by leading universities and medical schools, including the University of California, Massachusetts Institute of Technology, John Hopkins, Yale University, University of Texas, Stonybrook University, National Institute of Drug Abuse, University of Tulane, Concordia, McGill, Toronto, Chicago, Milan, Rome and the University of Colorado, are completed and ongoing. The completed data has been published in U.S. and foreign journals, including Science, Nature, Lancet, Molecular Psychiatry, Alcohol, Archives General Psychiatry, Biochemical Pharmacology, Gene therapy & Molecular Biology, Current Neuropharmacology, Theoretical Biology and Medical Modeling, Medical Hypotheses, Psychopharmacology, British Journal of Pharmacology and JAMA. There are 21 (so far at this writing) peer reviewed published clinical trials validating the efficacy of this groundbreaking technology.
Under normal conditions in the “reward system” of the brain, the neurotransmitter dopamine stimulates certain dopamine receptors that signal feelings of pleasure and well-being; reduce the effects of stress (increase stress tolerance); and promote satisfaction, satiety, and happiness. Certain gene variations, or polymorphisms, in the “brain reward cascade” cause the brain to need increased amounts of dopamine to feel good, i.e. a “dopamine fix.” This condition is also called ‘dopamine resistance,’ which can cause excessive pleasure/reward seeking behaviors. These behaviors include psychostimulant use/abuse, gambling, thrill seeking behaviors, sexual deviance, ADHD, and more; all done to get that dopamine fix. This results in a condition called “Reward Deficiency Syndrome” (RDS). Importantly, people who experience RDS also engage in excessive unhealthy craving behaviors to get that dopamine fix; are more prone to excess sugar and fat cravings and intake; generally overeat; and experience metabolic disruption. These people have the greatest genetic predispositions to and highest incidence of dopamine resistance.
Clinical Trial Data SynaptaGenX (SGX)
Obese Subjects (1)
Open label pre vs post treatment
DNA customized SGX administration yielded significant results for weight loss, sugar cravingreduction, appetite suppression, snack reduction, reduction of late night eating (all P<0.01 ), increased perception of overeating, enhanced quality of sleep, increased happiness (allP<0.05 ), and increased energy (P<0.001). (Adv Therp 25(9) 894,2008 Blum et al.)View/Download PDF
Obese Subjects (2)
Open label pre vs post treatment
DNA customized SGX administrationyielded significant Pre- and post ad hoc analysis revealed a significantdifference between the starting BMI and the BMI following an average of 41 days(28-70d) of SGX variant intake whereby 71.4% lost weight. (Gene Therapy & Mol Biol. 12,371,2008 Blum et al.)View/Download PDF
Alcoholic and Heroin Addicts
Open-label case study
We demonstrate for the first time that SGX intravenous administration reduces or “normalizes” aberrant electrophysiological parameters of the reward circuitry site. (Postgraduate Medicine 122(6) 188, 2010 Miller et al.)View/Download PDF
Controlled open label
Nine-fold decrease in AMA rate with SGX variant compared to controls. (Cur Ther Res43(6) 1204,1988Blum et al.)View/Download PDF
Randomized, triple-blind, placebo-controlled, crossover
SGX variant showed an increase of alpha waves and low beta wave activity in the parietal brain region one hour post administration.(Postgraduate Medicine 122(6) 214, 2010 Blum et al.)View/Download PDF
Randomized Double-blind placebo -controlled
SGX variant significantly reduced stress response as measured by skin conductance, compared to patients receiving placebo. (Gene Therapy & Molecu lar Biology Blum et al.)View/Download PDF
Poly-Drug Addicts Court Mandated
Open label out-patient 12 month clinical trial
SGX variant after 1 year yielded a significant decrease in depression, anger, anxiety, drug craving, increased energy. Drop out rate for alcoholics was only 7%. (Adv Therp 24(2), 402,2007 Chen et al.)View/Download PDF
Open label out-patient 12 month clinical trial comparison to non-treatment
The average number of days of compliance of being drug free utilizing Naltrexone in 1000 patients without SGX variant using rapid detoxification method is only 37 days. With SGX patients were relapse free for an average of 262 days (P<0.0001). (Med Hyp 63,538,2004 Chen et al.)View/Download PDF
Randomized double-blind placebo controlled
With SGX variants significantly improved Physical Scores and BESS Scores (behavioral, emotional, social and spiritual). After detoxification there was a six-fold decrease in AMA rates when comparing SGX variant vs. placebo groups. In this in-patient treatment experience SGX variant facilitated the rate of recovery and allowed patients to respond more fully and more quickly to the behavioral goals of the program. (Alcohol 5,481,1988 Blum et al.)View/Download PDF
Detoxified Poly-Drug Addicts
In-patient 30 day double-blind controlled
SGX variant patients as compared to controls (no SGX) had a lower Building Up To Drink Score (BUD), required no benzodiazepines (0 vs. 94%), ceased tremors at 72 hours as compared to 96 hours, had no severe depression on the MMPI compared to 24% in the control group. (International Journal of Addictions 23(9), 991,1988. Blum et al.)View/Download PDF
DUI Outpatient Offenders Alcohol and Cocaine
One year open label controlled (vitamin) clinical trial.
SGX variants significantly reduced relapse rates and enhanced recovery in DUI outpatient offenders over a 10 week period. After ten months SGX compared to controls revealed a 73% recovery rate in alcoholics and a 53% recovery rate in cocaine addicts. (Journal of Psychoactive Drugs, 22(2) 173,1990. Brown et al.)View/Download PDF
30 day open label pre-post evaluation
SGX variant induced a significant enhancement of focus as measured by P300 wave and computerized performance tasks. (Clin- Electroencephalogr. 28(2) 68,1997 Defrance et al.)View/Download PDF